Core Insights - XOMA Royalty Corporation reported over $50 million in cash receipts for the full year 2025, with a 9% increase in total receipts and a significant 68% rise in royalties compared to 2024 [1][7] - The company added 22 assets to its portfolio, including five programs in advanced Phase 2 or Phase 3 development [1][3] - A stock buyback program was executed, repurchasing 648,048 shares for a total of $16 million [1][3] - XOMA completed seven acquisitions, generating $11.7 million in non-dilutive capital and gaining economic interests in potential milestone payments of up to $1.1 billion [1][6] - Key pipeline events for 2026 include anticipated Phase 2b data from volixibat and Phase 3 data from ersodetug, along with potential EMA decisions on marketing authorizations for OJEMDA™ and MIPLYFFA™ [1][4] Financial Performance - In Q4 2025, XOMA Royalty received $3.2 million from royalties and $3.3 million from milestone payments, with a total of $50.5 million in cash receipts for the full year [7][8] - The company reported income and revenues of $13.8 million for Q4 2025, up from $8.7 million in Q4 2024, and $52.1 million for the full year 2025, compared to $28.5 million in 2024 [8][14] - General and administrative expenses increased to $10.4 million in Q4 2025 from $7.0 million in Q4 2024, primarily due to higher business development costs [9][10] Business Development - XOMA amended its collaboration with Takeda, which will yield low to mid-single-digit royalties and potential milestones of up to $852.6 million across nine development-stage assets [6] - The company has been active in acquisitions, completing seven since the beginning of 2025, which has strengthened its portfolio and financial position [6][11] Cash Position - As of December 31, 2025, XOMA Royalty had cash and cash equivalents of $133.7 million, including $50.8 million in restricted cash [15][29] - The company experienced a net increase in cash of $27.3 million during the year, compared to a decrease of $53.1 million in 2024 [29][30]

Core Viewpoint - XOMA Royalty Corporation announces the resignation of CFO Thomas Burns, who has been instrumental in the company's transition to a royalty aggregator, and appoints Jeffrey Trigilio as the new CFO to continue the company's growth strategy in the biotech sector [1][2]. Company Leadership Transition - Thomas Burns is stepping down after nearly two decades of service, with CEO Owen Hughes expressing gratitude for his contributions to the company's financial foundation and growth [2]. - Jeffrey Trigilio has been appointed as the new CFO, bringing extensive experience from various biotech companies and investment banks, including his recent role at Obsidian Therapeutics [2][3]. Strategic Direction - The leadership team, under Trigilio, aims to enhance the royalty portfolio through disciplined capital deployment, robust diligence, and innovative deal structuring to generate shareholder value [3]. - XOMA Royalty operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical companies, providing sellers with non-dilutive funding [3]. Portfolio Overview - XOMA Royalty's portfolio includes commercial assets such as VABYSMO, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY, and DSUVIA, with other assets being investigational compounds [6].

Core Viewpoint - XOMA Royalty Corporation has successfully sold its remaining Kinnate pipeline assets for up to $270 million in upfront and milestone payments, along with royalties on future commercial sales [1][2] Group 1: Financial Details - The total potential financial benefit from the sale includes up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens [1] - Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related payments made to XOMA Royalty prior to April 2, 2029 [2] Group 2: Company Background - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical or biotechnology companies [3] - The company provides non-dilutive, non-recourse funding to sellers, enabling them to advance their internal drug candidates or for general corporate purposes [3] Group 3: Current Portfolio - As of the date of the press release, XOMA Royalty's milestone and royalty portfolio includes commercial assets such as VABYSMO®, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY®, and DSUVIA® [6]